1) Smith, B. D., et al., 2019. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell 35: 738-751.

2) Protein Data Bank. https://www.rcsb.org/structure/6MOB

3) Foster, B. M., et al., 2018. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines 6: 31.

4) De Silva, C. M , Reid, R., 2003. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9: 13-19.

5) Ordog, T., Zornig, M., Hayashi, Y., 2015. Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Transl Med 4: 702-707.

6) Protein identification and analysis tools on the ExPASy server. Gasteiger, E. et. al. In J. M. Walker (Ed.) The proteomics protocols handbook. Totowa, New Jersey: Humana Press Inc. 2005.

7) Roskoski, R., 2005. Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor. Biochem. Biophys. Res Commun 338: 1307-1315.

8) Basic Local Alignment Search Tool. National Center for Biotechnology Information. 2012. http://www.ncbi.nlm.nih.gov/blast/Blast.cgi

9) Dali server: conservation mapping in 3D. Nucl. Acids Res. 38, W545-549. Holm L, Rosenström, P. 2010.

10) Wu, D., et al., 2016. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455. PLoS One 11: 1-11.